Education

Donate to Advance Research and Education
With your help, the American Neuromuscular Foundation can fund research that will improve the lives of patients with neuromuscular diseases.

Physician Podcasts

Sort by: Name Date Size

Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.

    7/3/2019
Dr. Elie Naddaf interviews Dr. Mazen Dimachkie on his article, Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis. To estimate the satisfactory response rate (SR%) with achieving maintenance, low-dose prednisone in acetylcholine receptor antibody-positive generalized myasthenia gravis. In this retrospective study, we estimate the SR% as defined by (remission/minimal manifestations status for at least 6 months using 7.5 mg or less of prednisone daily, for maintenance treatment at 2, 4, and 6 years after symptoms onset) for patients who were not taking steroid-sparing immunosuppressant (SSI) as a primary outcome and for patients taking an SSI as a secondary outcome. Forty-five patients were not taking an SSI at 2 years, 34 patients at 4 years, and 17 patients at 6 years; SR% was 44.4%, 64.7%, and 58.8%, respectively. Thirty-six patients were taking an SSI at 2 years, 22 patients at 4 years, and 15 patients at 6 years; the SR% was 50.0%, 45.4%, and 66.7%, respectively. Nearly half of the generalized myasthenia gravis patients who were not taking an SSI achieved an SR.

Muscle Biopsy EMG Correlation

    2/11/2019
Dr. Scott Speelziek interviews Dr. Naddaf Elie on his article, Muscle Biopsy EMG Correlation.

Electrodiagnostic Errors Contribute to Chronic Inflammatory Demyelinating Polyneuropathy Misdiagnosis.

    7/23/2018
Dr. Willer interviews Dr. Allen on their article, Electrodiagnostic Errors Contribute to Chronic Inflammatory Demyelinating Polyneuropathy Misdiagnosis.

Amyloid TTR treatment studies

    7/23/2018
Dr. Burns interviews Dr. Litchy and Dr. Jim & Peter Dyck on their article, Amyloid TTR treatment studies.

Whole Exome Sequencing by Dr. Daniel MacArthur

    4/16/2015
Whole Exome Sequencing and the Clinical Impact of Sequencing Techniques by Dr. Daniel MacArthur, interviewed by Dr. Ted Burns.

Next Generation Sequencing and its Impact on Neuromuscular Medicine by Dr. Daniel MacArthur

    4/13/2015
Next Generation Sequencing and its Impact on Neuromuscular Medicine by Dr. Daniel MacArthur interviewed by Dr. Ted Burns.

ALS Onset is Influenced by the Burden of Rare Variants in Known ALS Genes by Drs. Baloh and Harms

    3/27/2015
ALS Onset is Influenced by the Burden of Rare Variants in Known ALS Genes by Drs. Robert Baloh and Matthew Harms, interviewed by Dr. Ted Burns. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes.Ann Neurol. 2015 Jan;77(1):100-13. doi: 10.1002/ana.24306. Epub 2014 Nov 27.

Muscle intrusion as a potential cause of carpal tunnel syndrome by Dr. Michael Cartwright

    1/21/2015
Muscle intrusion as a potential cause of carpal tunnel syndrome by Dr. Michael Cartwright interviewed by Dr. Justin Willer. Muscle Nerve. 2014 Oct;50(4):517-22. doi: 10.1002/mus.24183. Epub 2014 Jun 16.

Dermatomyositis and Autoantibodies by Dr. Andrew L. Mammen

    12/18/2014
Dermatomyositis and Autoantibodies by Dr. Andrew L. Mammen. This is part three of a three part series on immune-mediated myopathies and autoantibodies.

Necrotizing Myopathies by Dr. Andrew L. Mammen

    12/11/2014
Necrotizing Myopathies by Dr. Andrew L. Mammen. This is part two of a three part series on immune-mediated myopathies and autoantibodies.

Antisynthetase syndrome and myositis by Dr. Andrew L. Mammen

    12/4/2014
Antisynthetase syndrome and myositis by Dr. Andrew L. Mammen. This is part one of a three part series on immune-mediated myopathies and autoantibodies.

Pathokinesiology of Duchenne Muscular Dystrophy

    11/25/2014
Ernest W. Johnson, MD discusses pathokinesiology of Duchenne muscular dystrophy: implications for management in Arch Phys Med Rehabil 1977;58:1-4. Interviewed by Ted Burns, MD and Gregory Carter, MD, MS.

Clinical Value of Motor Nerve Conduction Velocity Determination by Ernest W. Johnson, MD

    11/21/2014
An Interview with Ernest W. Johnson, MD, author of "Clinical Value of Motor Nerve Conduction Velocity Determination," an article appearing in JAMA 1960;172:2030-2035. Interviewed by Lawrence H. Phillips, II, MD and Gary Goldberg, MD. An introduction honoring the late Dr. Ernie Johnson is included.

Evidence-based Guideline Summary: Diagnosis and Treatment of Limb-Girdle and Distal Dystrophies

    11/13/2014
This podcast is an interview by Dr. Ted Burns with Drs. Anthony Amato and Pushpa Narayanaswami about the article: Evidence-based Guideline Summary: Diagnosis and Treatment of Limb-Girdle and Distal Dystrophies. A Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular and Electrodiagnostic Medicine.

Electrodiagnosis of Ulnar Neuropathy at the Elbow (Une): a Bayesian Approach.

    11/12/2014
This podcast, Electrodiagnosis of ulnar neuropathy at the elbow (Une): a Bayesian approach, is based on an article in Muscle Nerve. 2014 Mar;49(3):337-44. doi: 10.1002/mus.23913.

Myotonic Dystrophy Health Index: Initial Evaluation of a Disease-Specific Outcome Measure

    8/29/2014
Myotonic Dystrophy Health Index: Initial Evaluation of a Disease-Specific Outcome Measure by Dr. Chad Heatwole and interviewed by Dr. Nicholas Silvestri. From the Muscle and Nerve article: INTRODUCTION: In preparation for clinical trials we examine the validity, reliability, and patient understanding of the Myotonic Dystrophy Health Index (MDHI). METHODS: Initially we partnered with 278 myotonic dystrophy type-1 (DM1) patients and identified the most relevant questions for the MDHI. Next, we used factor analysis, patient interviews, and test-retest reliability assessments to refine and evaluate the instrument. Lastly, we determined the capability of the MDHI to differentiate between known groups of DM1 participants. RESULTS: Questions in the final MDHI represent 17 areas of DM1 health. The internal consistency was acceptable in all subscales. The MDHI had a high test-retest reliability (ICC = 0.95) and differentiated between DM1 patient groups with different disease severities. CONCLUSIONS: Initial evaluation of the MDHI provides evidence that it is valid and reliable as an outcome measure for assessing patient-reported health. These results suggest that important aspects of DM1 health may be measured effectively using the MDHI. Muscle Nerve. 2014 Jun;49(6):906-14. doi: 10.1002/mus.24097.

Vasculitic Neuropathies by Drs. Kelly Gwathmey and P. James B. Dyck interviewed by Dr. Ted Burns

    7/30/2014
This podcast discusses information from the article "Vasculitic Neuropathies" in Lancet Neurology. The vasculitic neuropathies are a diverse group of disorders characterised by the acute-to-subacute onset of painful sensory and motor deficits that result from inflammatory destruction of nerve blood vessels and subsequent ischaemic injury. They are common in patients with primary systemic vasculitis and are seen in vasculitis secondary to disorders such as rheumatoid arthritis, viral infections, and diabetic inflammatory neuropathies. It is imperative that neurologists recognise these disorders to initiate treatment promptly and thereby prevent morbidity and mortality. Lancet Neurol. 2014 Jan;13(1):67-82. doi: 10.1016/S1474-4422(13)70236-9.

Improving Referring Physicians' Understanding of EMG Reports When Qualifying Radiculopathies

    4/10/2014
Electromyographic (EMG) reporting of radiculopathies is not standardized, and the terminology used in reports can be misinterpreted by referring physicians. Physicians who refer patients for EMG studies at the Mayo Clinic were surveyed about their understanding of 6 different EMG interpretations of an S1 radiculopathy. Of 45 responders, the terms “acute, active,” “chronic, inactive,” and “old” were interpreted consistently by 95%, 98%, and 84% of responders, respectively. Physicians had the most difficulty understanding the meaning of “chronic” in isolation, “chronic, active,” or “old with uncompensated denervation.” These findings suggest a need to educate referring physicians on the meaning of the terms used in EMG reports and to develop standard guidelines for qualifying radiculopathies. Based on our observations, guidelines for the reporting of radiculopathies have been adopted in the Mayo Clinic Florida EMG laboratory. Muscle Nerve 49: 129–130, 2014

Exome Sequencing by Michael Shy, MD and Stephan Zuchner, MD

    3/10/2014
Exome sequencing discussion by Michael Shy, MD and Stephan Zuchner, MD, interviewed by Ted Burns, MD.

Spinal muscular atrophy: development and implementation of potential treatments

    12/19/2013
Spinal muscular atrophy: development and implementation of potential treatments by Drs. David Arnold and Arthur Burghes. Ann Neurol. 2013 Sep;74(3):348-62. doi: 10.1002/ana.23995. This podcast is a brief discussion of the article in Annals in Neurology. The article discusses the rapid progress in the understanding of recessive proximal spinal muscular atrophy and how this is leading to exciting potential treatments of the disease. Spinal muscular atrophy is caused by loss of the survival motor neuron 1 (SMN1) gene and reduced levels of SMN protein. The critical downstream targets of SMN deficiency that result in motor neuron loss are not known. However, increasing SMN levels has a marked impact in mouse models, and these therapeutics are rapidly moving toward clinical trials. Promising preclinical therapies, the varying degree of impact on the mouse models, and potential measures of treatment effect are reviewed. One key issue discussed is the variable outcome of increasing SMN at different stages of disease progression.

Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead by Dr. Blackhall

    11/21/2013
Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead by Dr. Leslie J. Blackhall, interviewed by Dr. Michael K. Hehir. Patients with amyotrophic lateral sclerosis (ALS) have high symptom burdens, including pain, fatigue, dyspnea, and sialorrhea, and they must make difficult decisions about the use of life-prolonging therapies, such as long-term mechanical ventilation. The impact of ALS is also felt by family caregivers who often struggle to meet the heavy physical, financial, and emotional demands associated with the illness. Expert multidisciplinary care may improve both quality and length of life of patients with ALS. However, although advances have been made in the treatment of some symptoms, others, including pain management, remain poorly studied. Involvement of palliative care specialists as part of the ALS multidisciplinary team is recommended, as we continue to work toward improving the quality of life for patients and their families. Muscle Nerve, 2012. The ideas and opinions expressed are solely those of the specific authors and do not necessarily represent those of AANEM.

Myasthenia Gravis and the use of IVIg and Therapeutic Plasma Exchange by Dr. Vern Juel

    8/30/2013
Dr. Elliot Dimberg interviews Dr. Vern Juel regarding the treatment of myasthenia gravis. Specifically, they discuss the use of intravenous immune globulin and plasma exchange. They present the indications, differences in use, and differences in risk between the two treatments, as well as differences between peripheral and central access.

Inherited Neuropathies: Clinical Overview and Update

    7/30/2013
Inherited Neuropathies: Clinical Overview and Update by Drs. Christopher Klein and Michael Shy interviewed by Dr. Laurie Gutmann. Muscle Nerve. 2013 Jan 30. doi: 10.1002/mus.23775

Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis by Dr.Steven Greenberg

    6/5/2013
Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis by Dr. Steven A. Greenberg interviewed by Dr. Ted Burns. Ann Neurol. 2013 Mar;73(3):408-18. doi: 10.1002/ana.23840.

Diagnostic Ultrasound of the Fibular (Peroneal) Nerve

    5/8/2013
Diagnostic Ultrasound of the Fibular (Peroneal) Nerve interviewed by Dr. Ted Burns.
1
 
2
 
3
 
4
 
5

Advertisement

ABEM

Advertisement

TPP

Advertisement

CSL Behring